Provided by Tiger Trade Technology Pte. Ltd.

Relay Therapeutics

19.44
-0.2600-1.32%
Post-market: 19.500.0600+0.31%19:56 EDT
Volume:2.97M
Turnover:58.13M
Market Cap:4.26B
PE:-12.42
High:20.17
Open:19.92
Low:19.18
Close:19.70
52wk High:21.27
52wk Low:3.43
Shares:219.14M
Float Shares:145.00M
Volume Ratio:1.41
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5651
EPS(LYR):-1.6113
ROE:-36.77%
ROA:-22.88%
PB:4.79
PE(LYR):-12.06

Loading ...

Relay Therapeutics Inc : Jonestrading Initiates Coverage With Hold Rating; Target Price $18

THOMSON REUTERS
·
Apr 14

Relay Therapeutics initiated with a Hold at JonesResearch

TIPRANKS
·
Apr 14

Relay CFO Thomas Catinazzo disposes of Relay Therapeutics shares worth $257,775

Reuters
·
Apr 10

Relay Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Apr 09

Relay to present initial clinical data for zovegalisib in vascular anomalies at ISSVA 2026

Reuters
·
Apr 03

Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

GlobeNewswire
·
Apr 03

Did Phase 1/2 ReDiscover Data Just Reframe Relay Therapeutics' (RLAY) Late-Stage Breast Cancer Strategy?

Simply Wall St.
·
Mar 24

Relay Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 23

Relay Therapeutics price target raised to $19 from $14 at H.C. Wainwright

TIPRANKS
·
Mar 23

Relay Therapeutics: Encouraging Zovegalisib Phase 3 Prospects, Strong Cash Runway, and Raised Price Target Support Buy Rating

TIPRANKS
·
Mar 23

Relay Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Mar 17

Relay Therapeutics price target raised to $17 from $15 at Citizens

TIPRANKS
·
Mar 17

Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients?

Benzinga_recent_news
·
Mar 16

Relay Therapeutics Highlights Positive Zovegalisib ReDiscover Trial Data

TIPRANKS
·
Mar 16

Relay Therapeutics announces data from Phase 1/2 ReDiscover trial

TIPRANKS
·
Mar 16

Relay Therapeutics reports 11.1-month median PFS for zovegalisib plus fulvestrant at 400 mg BID fed in Phase 1/2 ReDiscover trial

Reuters
·
Mar 16

Relay Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 13

Guggenheim Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

TIPRANKS
·
Mar 13

Relay Therapeutics Updates Bylaws on Federal Securities Litigation

TIPRANKS
·
Mar 12

Relay Therapeutics Adopts Federal Court Exclusive Forum Bylaw for Securities Act Claims

Reuters
·
Mar 12